title: Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up.
authors.forename: P
authors.initials: P
authors.lastname: Hupperets
authors.forename: J
authors.initials: J
authors.lastname: Wils
authors.forename: L
authors.initials: L
authors.lastname: Volovics
authors.forename: L
authors.initials: L
authors.lastname: Schouten
authors.forename: M
authors.initials: M
authors.lastname: Fickers
authors.forename: H
authors.initials: H
authors.lastname: Bron
authors.forename: H
authors.initials: H
authors.lastname: Schouten
authors.forename: J
authors.initials: J
authors.lastname: Jager
authors.forename: J
authors.initials: J
authors.lastname: de Jong
authors.forename: L
authors.initials: L
authors.lastname: Beex
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D017258:Medroxyprogesterone Acetate; D005472:Fluorouracil